ADAR1通过神经细胞介导的神经元亡加剧缺血性脑损伤
Dunpeng Cai1, Mikayla Fraunfelder1, Ken Fujise2
1Departments of Surgery, University of Missouri School of Medicine, Columbia, MO, USA.
Redox biology
|October 6, 2023
概括
作用于RNA (ADAR1) 的腺氨酸脱氨酶促进了缺血性中风后的星球细胞增殖和炎症,恶化了结果. 抑制ADAR1可以减少大脑损伤和神经元亡,这表明ADAR1是治疗目标.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 病理学 病理学 病理学
背景情况:
- 星球细胞通过采用特定的功能状态,在中风的结果中发挥着关键作用.
- 了解神经细胞激活后缺血的分子驱动因素对于开发新的中风疗法至关重要.
研究的目的:
- 研究腺氨酸脱氨酶作用于RNA (ADAR1) 在星球细胞功能中的作用及其对缺血性中风结果的影响.
- 阐明ADAR1影响中风后天体细胞增殖,炎症和神经元亡的分子机制.
主要方法:
- 在小鼠中使用中脑动脉阻塞 (MCAO) 模型来诱导缺血性中风.
- 在MCAO后的天体细胞中分析ADAR1表达.
- 在ADAR1缺乏的小鼠中评估神经缺陷和心脏病发作量.
- 在实验室中使用初级天体细胞培养和神经元亡试验进行的研究.
主要成果:
- 在缺血性中风后的星细胞中,ADAR1表达显著诱导,在MCAO后的1-7天之间达到峰值.
- 缺少ADAR1显著降低了脑梗塞的数量和神经系统缺陷.
- ADAR1通过PI3K/Akt通路促进星体细胞的增殖,并增强炎症性细胞因子 (IL-1β,IL-6,TNF-α) 的分泌.
- 在体内和体外,ADAR1缺乏抑制了神经元亡,与减少反应性氧物种的产生有关.
结论:
- ADAR1是缺血性中风后天体细胞激活和增殖的关键调节者.
- 通过炎症性细胞因子生产,ADAR1有助于中风诱导的神经元亡和不良结果.
- 向ADAR1为减轻缺血性中风损伤提供了一个潜在的治疗策略.
相关概念视频
Alzheimer's Disease: Overview
506
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
506
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212


